Source https://www.fightaging.org/archives/2019/07/a-mainstream-view-of-the-longevity-industry/
This popular science article from the AARP is representative of the sort of outsider’s view of the longevity industry that is presently dominant. On the one hand, it is good that the media and advocacy organizations such as AARP are finally talking seriously about treating aging as a medical condition. On the other hand, the author looks at two of the most popular areas of development, mTOR inhibitors and senolytics, in a way that makes them seem more or less equivalent, and then further adds diet and exercise as another equivalent strategy. This will be continuing issue, I fear. People, as a rule, don’t think about size of effect and quality of therapy when discussing present initiatives.
These strategies are in fact very different, and the differences are important. Clearance of <a href="https://en.wikipedia.org/wiki/Ce…
Source https://www.fightaging.org/archives/2019/07/a-mainstream-view-of-the-longevity-industry/
This popular science article from the AARP is representative of the sort of outsider’s view of the longevity industry that is presently dominant. On the one hand, it is good that the media and advocacy organizations such as AARP are finally talking seriously about treating aging as a medical condition. On the other hand, the author looks at two of the most popular areas of development, mTOR inhibitors and senolytics, in a way that makes them seem more or less equivalent, and then further adds diet and exercise as another equivalent strategy. This will be continuing issue, I fear. People, as a rule, don’t think about size of effect and quality of therapy when discussing present initiatives.
These strategies are in fact very different, and the differences are important. Clearance of <a href="https://en.wikipedia.org/wiki/Ce…
What Do You Think?
comments